Welcome to our dedicated page for Septerna SEC filings (Ticker: SEPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Septerna, Inc. (Nasdaq: SEPN) SEC filings, offering detailed regulatory disclosures about the company’s operations as a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery. As an issuer with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC or The Nasdaq Global Market, Septerna files current and periodic reports that describe its business, governance and financial condition.
Septerna’s Form 8-K filings frequently cover material events such as quarterly financial results and business highlights, including revenue, research and development expenses, general and administrative expenses, net income or loss, cash and marketable securities, working capital, total assets, total liabilities and stockholders’ equity. Other 8-Ks disclose collaboration agreements, such as the global collaboration and license agreement with Novo Nordisk A/S, leadership and board appointments, executive role changes, investor presentations and annual meeting voting results.
Through its SEC filings, Septerna also reports on matters like director elections, committee assignments, non-employee director compensation, and submission of matters to a vote of stockholders. These documents provide insight into the company’s corporate governance framework, including the composition of its board and committees and the outcomes of shareholder votes.
On Stock Titan, Septerna’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the key points of lengthy filings, so readers can quickly understand the implications of new 8-Ks and other reports without reviewing every page. Users can review historical filings to track trends in Septerna’s financials, follow the evolution of its collaborations and governance, and monitor ongoing disclosure about its GPCR-focused pipeline and clinical-stage programs.
Septerna, Inc. reported a stock option grant to its Chief Executive Officer and director, Jeffrey Finer. On February 6, 2026, he was awarded a stock option to purchase 400,000 shares of Septerna common stock at an exercise price of $25.41 per share.
The option expires on February 5, 2036. According to the vesting schedule, 2/48 of the shares will vest and become exercisable on March 1, 2026, and the remaining shares will vest in 46 substantially equal monthly installments, subject to his continuous service with the company.
Septerna, Inc. reported a stock option grant to its Chief Executive Officer and director, Jeffrey Finer. On February 6, 2026, he was awarded a stock option to purchase 400,000 shares of Septerna common stock at an exercise price of $25.41 per share.
The option expires on February 5, 2036. According to the vesting schedule, 2/48 of the shares will vest and become exercisable on March 1, 2026, and the remaining shares will vest in 46 substantially equal monthly installments, subject to his continuous service with the company.
Septerna, Inc. reported that its Chief Legal Officer, Mark Andrew Wilson, received a grant of stock options on February 6, 2026. The grant covers 165,000 stock options, each allowing the purchase of one share of Septerna common stock at an exercise price of $25.41 per share.
According to the vesting terms, 25% of the shares underlying the option will vest on January 5, 2027, with the remaining 75% vesting in thirty-six substantially equal monthly installments after that date, contingent on his continued service with the company.
Septerna, Inc. reported that its Chief Legal Officer, Mark Andrew Wilson, received a grant of stock options on February 6, 2026. The grant covers 165,000 stock options, each allowing the purchase of one share of Septerna common stock at an exercise price of $25.41 per share.
According to the vesting terms, 25% of the shares underlying the option will vest on January 5, 2027, with the remaining 75% vesting in thirty-six substantially equal monthly installments after that date, contingent on his continued service with the company.
Septerna, Inc. filed an initial insider ownership report for its Chief Legal Officer, Mark Andrew Wilson. This Form 3 filing identifies Wilson as an officer of the company but states that he does not beneficially own any Septerna securities at the time of the report. The document also includes a power of attorney authorizing the filing on his behalf.
Septerna, Inc. filed a Form 8-K to notify investors that the company will be holding meetings with participants at the 44th Annual J.P. Morgan Healthcare Conference during the week of January 12, 2026. The company prepared an investor presentation for these meetings, which is furnished as Exhibit 99.1 and incorporated by reference. This material is being provided as "furnished" information under Item 7.01, meaning it is not treated as filed for liability purposes or automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.
Septerna, Inc. filed a current report describing a leadership expansion. On January 8, 2026, the company issued a press release announcing the appointment of industry veteran Mark A. Wilson as Chief Legal Officer. The press release is included as Exhibit 99.1 and is incorporated by reference for additional details.
The disclosure is made under Regulation FD, meaning the company is sharing information intended to keep all investors equally informed. The information in this item and Exhibit 99.1 is furnished rather than filed, so it is not subject to certain liability provisions of the Exchange Act unless specifically incorporated into another filing.
Septerna, Inc. (SEPN) Form 4: An executive identified as SVP, Drug Discovery reported a sale of 3,501 shares of common stock on 11/10/2025, coded “S.” The weighted average sale price was $18.0586.
The filing notes sales occurred across a price range of $18.04 to $18.16. Following the transaction, the reporting person beneficially owns 92,911 shares, held directly.
According to the footnote, this figure includes 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on 10/31/2025 in transactions exempt under Rule 16b-3(c).
Septerna, Inc. reported a profitable Q3 2025 as collaboration revenue ramped and interest income increased. Revenue was $21,495 thousand for the three months ended September 30, 2025, up from $176 thousand a year ago, reflecting recognition under its Novo Nordisk collaboration. The company recorded net income of $8,173 thousand in Q3 2025, compared to a net loss of $20,523 thousand in Q3 2024. Results also included a $12,500 thousand gain on sale of a non‑financial asset tied to a Vertex milestone.
Liquidity strengthened with cash, cash equivalents and marketable securities of $561,600 thousand as of September 30, 2025. Deferred revenue was $182,250 thousand (current $61,603 thousand; non‑current $120,647 thousand) from the $195,000 thousand Novo upfront received in July 2025, of which $12,750 thousand was recognized year‑to‑date. R&D expense was $24,264 thousand and G&A was $7,117 thousand in Q3 2025. Shares outstanding were 44,774,192 as of November 4, 2025.
Septerna, Inc. (SEPN) filed an 8-K announcing results and business highlights for the quarter ended September 30, 2025. The company furnished a press release as Exhibit 99.1 detailing the update.
The information under Item 2.02, including Exhibit 99.1, is being furnished, not deemed “filed” under the Exchange Act. Septerna’s common stock trades on the Nasdaq Global Market under the symbol SEPN.
Septerna, Inc. director Keith Michael Gottesdiener was granted a stock option to purchase 33,246 shares of common stock with an exercise price of $16.75. The option was issued on 09/25/2025, becomes exercisable in monthly installments equal to 1/36th of the shares beginning on that date (subject to continued service), and expires on 09/24/2035. Following the reported transaction, the reporting person beneficially owned 33,246 option shares, held directly. The Form 4 was signed via attorney-in-fact on 09/29/2025. No other securities or cash transactions are reported.
Septerna, Inc. (SEPN) director Keith Michael Gottesdiener filed an initial Form 3 disclosing his relationship to the issuer and stating no securities are beneficially owned. The filing lists his address at Septerna, Inc., identifies him as a director, and is signed by an attorney-in-fact on his behalf. The form reports the event date as 09/25/2025.